An assessment of iloperidone for the treatment of schizophrenia

Bibliography

• GOLDSTEIN JM: Atypical antipsychotic drugs: beyond acute psychosis, new directions. Emerging Drugs (1999) 4:127–151.
   Google Scholar
• ••Excellent review of schizophrenia in relation to the develop-ment and use of antipsychotic drugs, pointing out the advantages of atypical antipsychotics.
   Google Scholar
• KAPUR S, ZIPURSKY RB, REMINGTON G: Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone and olanzapine in schizophrenia. Am. J Psychiatry (1999) 156:286–293.
   PubMed Web of Science ®Google Scholar
• HARRISON PJ: Advances in postmortem molecular neurochemistry and neuropathology: examples from schizophrenia research. Br. Med. Bull. (1996) 52\(No. 3):527–538.
   Google Scholar
• SEDVALL G, PAULI S, KARLSSON P et al: PET imaging of neuroreceptors in schizophrenia. Eur. Neuropsycho-pharmacol. (1995) 5 (Suppl.):25–30.
   Google Scholar
• NGAN ET, YATHAM LN, RUTH TJ et al.: Decreased serotonin 2A receptor densities in neuroleptic-naive patients with schizophrenia: A PET study using [(1 8)F]setoperone. Am. J. Psychiatry (2000) 157:1016–1018.
   PubMed Web of Science ®Google Scholar
• BORISON RL: The role of cognition in the risk-benefitand safety analysis of antipsychotic medication. Acta Psychiatr. Scand. (1996) 389 (Suppl.):5–11.
   Google Scholar
• TUUNAINEN A, WAHLBECK K, GILBODY SM: Newer atypical antipsychotic medication versus clozapine for schizophrenia. Cochrane Database Syst. Rev. 2000 2 :CD000966.
   Google Scholar
• ••Comparison of the clinical trial data for various newlyintroduced atypical antipsychotics with that of clozapine.
   Google Scholar
• JAIN KK: Commercial opportunities in serotonin modifying drugs. Decision Resources Inc, Waltham, Massachusetts (1999).
   Google Scholar
• ••A review of pharmacology and commercial aspects ofvarious serotonin modulating drugs including antipsychotics.
   Google Scholar
• SZCZEPANIK AM, BROUGHAM LR, ROEHR JE et al.: Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-1-1T2 receptor antagonist activity. J. Pharmacol. Exp. Ther. (1996) 278:913–920.
   PubMed Web of Science ®Google Scholar
• KALKMAN HO, SUBRAMANIAN N, HOYER D: iloperi-done: the management of psychiatric disorders through broad spectrum dopamine/serotonin/ noradrenaline antagonism. Neuropsychopharmacology (2000). (In Press).
   Google Scholar
• MOLLER HJ: Management of psychotic illness through novel neurotransmitter modulation. CNIP (July 2000) Brussels, Belgium.
   Google Scholar
• SZEWCZAK MR, CORBETT R, RUSH DK et al.: The pharmacological profile of Iloperidone, a novel atypical antipsychotic agent. J. Pharmacol. Exp. Ther. (1995) 274:1404–1413.
   PubMed Web of Science ®Google Scholar
• ••An excellent review of pharmacology of iloperidone.
   Google Scholar
• STRUPCZEWSKI JT, BORDEAU KJ, CHIANG Y et al.: 3-[[(Aryloxy)alkyl]piperidinyl]-1,2-benzisoxazoles as D2 /5 -HT2 antagonists with potential atypical antipsy-chotic activity: antipsychotic profile of iloperidone (HP 873). J. Med. Chem. (1995) 38:1119–1131.
   PubMed Web of Science ®Google Scholar
• CACCIA S: Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin. Pharmacokinet. (2000) 38:393–414.
   PubMed Web of Science ®Google Scholar
• MUTLIB AE, STRUPCZEWSKI JT, CHESSON SM: Applica-tion of hyphenated LC/NMR and LC/MS techniques in rapid identification of in vitro and in vivo metabolites of iloperidone. Drug Metab. Dispos. (1995) 23:951–964.
   PubMed Web of Science ®Google Scholar
• MUTLIB AE, KLEIN JT: Application of liquid chromatog-raphy/mass spectrometry in accelerating the identifi-cation of human liver cytochrome P450 isoforms involved in the metabolism of iloperidone. J. Pharmacol. Exp. Ther. (1998) 286:1285–1293.
   PubMed Web of Science ®Google Scholar
• CHESSON SM, HSU RS, DILEO EM, STRUPCZEWSKI JT: HP 873, a potential atypical antipsychotic agent: pharma-cokinetics in rats and dogs. Pharmacologist (1991) 33:177–182.
   Google Scholar
• CORBETT R, GRIFFITHS L, SHIPLEY JE et al.: iloperidone:Preclinical profile and early clinical evaluation. CNS Drug Rev. (1997) 3:120–147.
   Google Scholar
• MORRA C, LASSER R, KLONOWSKI E: The ReALIZe Clinical Program: key role of study ILP3003. American Psychiatric Association Latin America Meeting (September 2000).
   Google Scholar
• KONGSAMUT S, ROEHR JE, CAI J et al.: iloperidone binding to human and rat dopamine and 5-HT receptors. Eur. Pharmacol. (1996) 317:417–423.
   PubMed Web of Science ®Google Scholar
• SAINATI SM, HUBBARD JW, CHI E et al.: Safety, tolerability and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsy-chotic. j Clin. Pharmacol. (1995) 35:713–720.
   PubMed Web of Science ®Google Scholar
• BORISON RL, HUFF FJ, GRIFFITHS L: Efficacy of 5 mg/day and 8 mg iloperidone administered to schizophrenic patients for 42 days. Psychopharmacol. Bull. (1996) 32:416.
   Web of Science ®Google Scholar
• LASSER RA, GUVEN A: A prospective, randomised,double-blind, placebo-controlled, flexible dose, parallel group, single-centre study to evaluate the safety, tolerability and efficacy of iloperidone (0.5 to 6 mg/day B.I.D.) compared with placebo in treating psychotic and behavioural symptoms in elderly patients with dementia. American Association of Geriatric Psychiatry Meeting (2000).
   Google Scholar
• MARKOVITS-GUPTA T, CUCCHIARO J, FAIRWEATHER D et al.: Managing Psychotic Disorders through receptor blockade: the ZomarilTmclinical program. XI World Congress of Psychiatry (August 1999) Hamburg, Germany.
   Google Scholar